Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4Y0 | ISIN: KYG0028A1085 | Ticker-Symbol: 8ZD
Frankfurt
28.03.24
08:59 Uhr
0,308 Euro
-0,002
-0,65 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ABBISKO CAYMAN LTD Chart 1 Jahr
5-Tage-Chart
ABBISKO CAYMAN LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,3940,47427.03.

Aktuelle News zur ABBISKO CAYMAN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN-
20.03.ABBISKO-B (02256): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS1
20.03.ABBISKO-B (02256): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS1
20.03.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN1
13.03.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN1
13.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE1
12.03.ABBISKO-B (02256): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ...1
28.02.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DELIVERED ORAL PRESENTATION OF PRELIMINARY FIRST-IN-HUMAN TRIAL RESULTS OF ITS HIGHLY ...1
26.02.ABBISKO-B (02256): DATE OF BOARD MEETING-
23.02.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT DOSE OF NEXT-GENERATION EGFR EXON20INS INHIBITOR ABSK112 COMPLETED BY ABBISKO THERAPEUTICS1
06.02.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTO A LICENSING AGREEMENT FOR PIMICOTINIB (ABSK021) ...1
01.02.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE POST-IPO RSU SCHEME1
10.01.Abbisko Therapeutics' Cancer Drug Gets EU's Orphan Drug Label3
09.01.Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib (ABSK021)324SHANGHAI, Jan. 8, 2024 /PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor pimicotinib(ABSK021)...
► Artikel lesen
09.01.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CSF-1R INHIBITOR PIMICOTINIB GRANTED ODD BY EMA1
03.01.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CD73 INHIBITOR ABSK051 COMPLETED THE FIRST PATIENT DOSE1
14.12.23Abbisko tenosynovial giant cell tumour therapy gains fast track status2
14.12.23ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CSF-1R INHIBITOR PIMICOTINIB (ABSK021) GRANTED FAST TRACK DESIGNATION BY U.S. FDA2
12.12.23HSBC raises Abbisko (02256) to HKD6.21
06.12.23Merck gains rights to Abbisko's pimicotinib in deal worth over $70m11
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1